Gilead Sciences, Inc. GILD today announced that the European
Commission has granted marketing authorization for two new indications for
once-daily Viread^® (tenofovir disoproxil fumarate). The first new indication
permits the use of Viread in combination with other antiretroviral agents for
the treatment of HIV-1 infected pediatric patients aged 2 to less than 18
years with nucleoside reverse transcriptase inhibitor (NRTI) resistance or
toxicities precluding the use of first line pediatric agents. Additionally,
Viread is now approved for the treatment of chronic hepatitis B virus (HBV)
infection in adolescent patients aged 12 to less than 18 years with
compensated liver disease and evidence of immune active disease. Today's
authorization covers all 27 countries of the European Union (EU). Viread was
approved for use in combination with other antiretroviral agents as a
treatment for HIV-1 infection in adults and for chronic HBV in 2002 and 2008,
respectively, and is the most-prescribed molecule for these diseases in major
European countries.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in